{"filing":{"accession_number":"0001493152-26-024365","cik":"0001535955","ticker":"LPCN","company_name":"Lipocine Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226024365/form8-k.htm"},"events":[{"id":10183,"run_id":8929,"accession_number":"0001493152-26-024365","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Lipocine announced that its LPCN 1154 Phase 3 clinical trial data has been accepted for oral presentation at the 2026 ASCP Annual Meeting (May 26-29, 2026). This represents a material clinical development milestone for a biopharmaceutical company, as Phase 3 data acceptance for oral presentation at a major medical conference signals positive trial results and advances the drug candidate toward potential regulatory approval. While this does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, executive change, or other specifically enumerated categories), it is material to investors evaluating the company's pipeline and prospects.","company_name":"Lipocine Inc.","ticker":"LPCN","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":300,"accession_number":"0001493152-26-024365","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Lipocine announced that its LPCN 1154 Phase 3 clinical trial data has been accepted for oral presentation at the 2026 ASCP Annual Meeting (May 26-29, 2026). This represents a material clinical development milestone for a biopharmaceutical company, as Phase 3 data acceptance for oral presentation at a major medical conference signals positive trial results and advances the drug candidate toward potential regulatory approval. While this does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, executive change, or other specifically enumerated categories), it is material to investors evaluating the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:42:00.476006+00:00","company_name":"Lipocine Inc.","ticker":"LPCN","filing_date":"2026-05-19"}]}